Purpose GPA33 is a colorectal cancer (CRC) antigen with unique retention properties after huA33-mediated tumor targeting. We tested a pretargeted radioimmunotherapy (PRIT) approach for CRC using a tetravalent bispecific antibody with dual specificity for GPA33 tumor antigen and DOTA-Bn-(radiolanthanide metal) complex. Methods PRIT was optimized in vivo by titrating sequential intravenous doses of huA33-C825, the dextran-based clearing agent, and the C825 haptens and safe targeted radiotherapy of established human colorectal mouse xenografts.
Introduction
Despite therapeutic advances in the last decade, colorectal cancer (CRC) is still the fourth leading cause of death worldwide, and 49,700 CRC deaths are projected for 2015 in the US alone [1] . Although locoregional therapies such as surgery and radiation can be curative in many cases, these approaches do not control tumors that have metastasized at diagnosis, for which chemotherapy and targeted small molecules are most often palliative, with rapid development of resistance. Clearly, there is an unmet need for improved therapeutics, particularly for the treatment of unresectable metastatic disease. In principle, targeted radiation therapy strategies such as radioimmunotherapy (RIT) could potentially address this unmet need, because they enable delivery of tumoricidal radiation doses to multiple systemically dispersed sites simultaneously (e.g., ranging from macroscopic nodal or hepatic oligometastases to occult micrometastatic disease) as long as the therapeutic indices (TIs) are favorable [2] . Notably, the majority of RIT trials in CRC have been with IgGs directed at carcinoembryonic antigen (CEA) (e.g., 131 I-hMN-14 [3] and 90 Y-cT84.66 [4] ). So far, these studies have had only limited clinical success because of suboptimal TIs of only 5 -10:1 for macroscopic tumors, which is inadequate for curative therapy without dose-limiting hematologic toxicity.
Since particularly radioresistant solid tumors such as CRC may require a total absorbed dose of 7,000 -10,000 cGy for cure, we need highly selective tumor targeting with respect to radiosensitive normal tissues (typically bone marrow, which may be suppressed by doses as low as 150 cGy). The RIT approach that offers the greatest potential for improving TI is the pretargeted approach (PRIT) utilizing bispecific antibodies (BsAb) [5] . For small-volume or microscopic disease, there is evidence that uptake, and consequently TI, may be higher in both animal models [6, 7] and human patients [8, 9] . This, taken in conjunction with the reduced tumor cell number in such small tumors, means that the likelihood of achieving complete ablation can be expected to be greater than in macroscopic disease, as long as a radionuclide appropriate for small-volume disease is used [10] . However, in the most general case, small-volume disease will coexist with macroscopic disease in the same patient and treatment approaches are required that address the entire disease spectrum. Moreover, if PRIT can improve the treatment of macroscopic disease, it will concomitantly improve that of microscopic disease by the same mechanisms and at no additional cost.
PRIT, a concept that separates the delivery of the targeting antibody to tumor from the delivery of the radioactivity, was initially developed by Reardan et al. [11] , Goodwin et al. [12] , and Feng et al. [13] using anti-radiometal chelate antibodies. The initial uptake studies demonstrated the proof of principle for this approach, showing improved tumor targeting compared to conventional RIT, but TIs were still suboptimal, partly because of the insufficient retention (on the order of several hours) of the radioactivity when carried by anti-chelate antibodies of only nanomolar affinity [14, 15] . The BsAb/radiometal binding approach took a major step forward with the development of ultra-high affinity antibodies for the radiometal-chelate binding step, based on the work of Orcutt et al. [16] at the Massachusetts Institute of Technology (MIT). Guided by a mathematical modeling approach that predicted the optimal required affinity of the hapten antibody binding step in PRIT, the MIT team, using directed evolution and yeast surface display, was able to affinity mature by more than 1000-fold to the low picomolar range the original 2D12.5 antibody specific for the benzyl(Bn)-DOTA-metal complex, now reformatted as the BC825^single-chain variable fragment (scFv) [16] . Next, the MIT team engineered BsAbs incorporating the C825 sequence utilizing a highly modular IgG-scFv scaffold (e.g., anti-CEA/C825) [17] . These IgG-scFv antibody compositions are tetravalent molecules, consisting of two binding sites for tumor antigen (typically, about 10 nM), and two binding sites for the Bn-DOTA-radiometal hapten (about 10 -20 pM).
We recently adopted this methodology for PRIT by focusing on anti-GD2 antibodies with a documented record of safe use and proven tumor localization in humans [18] . For CRC, we reasoned that the GPA33 target could be ideal for PRIT. GPA33 is a transmembrane glycoprotein abundantly expressed in over 95 % of CRCs, with restricted expression in normal tissue (colon and bowel epithelium) [19] . It exhibits long-term residence in cell membrane in tumors, relative to intestine, with minimal internalization and minimal vascular shedding. Using a variety of radiolabeled antibody forms, including initially a murine monoclonal antibody (A33 [20] ) and subsequently a humanized version (huA33 [21] ), this antigen is one of the most extensively studied targets in vivo. For example, we have performed 124 I-huA33 imaging in patients with CRC and confirmed through kinetic modeling that the differential clearance between antigen-positive tumor and antigen-positive intestine would yield TIs sufficient for tumor response to PRIT [8, 22, 23] .
As we developed PRIT, the need for radiation dosimetry based on quantitative imaging for measurement of timedependent activity distribution in tumor and normal tissues for optimal translation of PRIT to humans became apparent. Combined therapeutic and diagnostic, or Btheranostic,^PRIT refers to the use of reagents with virtually identical chemistries as vehicles for both diagnostic and therapeutic applications.
We have previously described successful applications of this approach using PET imaging of 124 I as a surrogate for 131 I therapy in thyroid cancer [24] [25] [26] . In the present studies, we applied 177 Lu as both the therapeutic (β-emission for RIT) and diagnostic (γ-emission for imaging) radionuclide, and Lu because the lower β-emission energy and short path length make it more likely to eradicate small tumors, in comparison to a longer β-emission path length radionuclide such as 90 Y. In the study reported here, we tested the principal hypothesis that optimized theranostic PRIT based on GPA33 antigen tumor targeting and a BsAb-huA33 construct can be used to achieve the high TIs required for effective and safe CRC therapy in xenografts in mice and, ultimately, in humans.
Materials and methods

Cloning and expression of huA33-C825
HuA33-C825 was prepared using the sequences for huA33 [21] and C825 [16] , a murine scFv antibody with high affinity for DOTA-radiometal complexes (Fig. 1a) . The BsAb was made using the same platform as control hu3F8-C825 [18] , only replacing variable regions (VH and VL) of hu3F8 with those of huA33 [21] . The IgG-scFv BsAb (molecular weight about 210 kDa) was produced in CHO cells and purified by protein A affinity chromatography as previously described [18] .
Surface plasmon resonance studies
A Biacore T100 biosensor, a CM5 sensor chip, and related reagents were purchased from GE Healthcare. The human GPA33 recombinant protein was purchased from Novoprotein. A BSA-(Y)-DOTA-Bn conjugate was prepared as previously described [18] . Both antigens were immobilized using the amine coupling kit (GE Healthcare). Purified BsAbs and control antibodies were analyzed and data fit to a bivalent analyte model using the Biacore T100 evaluation software as previously described [18] .
Anti-GPA33 PRIT reagents, protocol, and xenograft studies The GPA33(+) human CRC cell line SW1222 was obtained from the Ludwig Institute for Cancer Immunotherapy (New York, NY). SW1222 is notable among commonly investigated human CRC cell lines for preclinical RIT [27] [28] [29] [30] in that it forms relatively well-differentiated and highly vascular subcutaneous (s.c.) tumors and is thus well-suited to antibody targeting [31] . 131 I-A33 was used to demonstrate that a dose of 68 Gy to SW1222 tumors resulted in cures [29] . Details regarding the culturing of SW1222 and inoculation into immunocompromised mice are provided in the Supplementary material. Established tumors (50 -700 mm 3 ) were observed in 7 -10 days; tumor volumes (TVs) were estimated using the formula for the volume (V) of an ellipsoid: V=4/3π(length/2× width/2×height/2), with dimensions in millimeters. All reagents were administered intravenously via a lateral tail vein.
The anti-GPA33 PRIT protocol included injections of the following three reagents. HuA33-C825 BsAb (0.25 mg, 1.19 nmol) was injected first to allow localization in the tumor (t=−28 h). At t=−4 h 24 h later circulating BsAb was cleared by injection of a clearing agent (CA; 62.5 μg, 0.125 nmol) comprising a 500-kDa dextran-(Y)-DOTA-Bn conjugate prepared as previously described by Orcutt et al. [32] and formulated in saline for injection (7. 625 nmol of (Y)-DOTA-Bn). Finally, 4 h after injection of CA, the 177 Lu-DOTA-Bn was injected (t=0 h). Radiolabeled DOTA-Bn was prepared as previously described [18] Supplementary Fig. 1 ).
Micro single-photon emission computed tomography integrated with X-ray computed tomography (X-SPECT/CT) imaging was performed on selected mice during PRIT optimization. In addition, separate biodistribution studies were conducted with huA33-C825 trace radiolabeled with 131 I (Nordion) to estimate tumor uptake during PRIT (i.e., at 24 h post-injection, p.i.). Details regarding X-SPECT/CT imaging, tracer preparation and quality control, as well as the ex vivo biodistribution analysis of radioactivity following radiotracer injection are provided in the Supplementary material.
PET imaging of anti-GPA33 PRIT + 86 Y-DOTA-Bn
A single group of five mice bearing GPA33(+) SW1222 tumors in the shoulder were given PRIT (as described above) using 8.6 -8.8 MBq (about 50 pmol) of 86 Y-DOTA-Bn, and noninvasively imaged at approximately 2 and 20 h p.i. using a microPET Focus 120 (CTI Molecular Imaging, Inc., Knoxville, TN) and previously described methods [33] . A detailed description of the imaging protocol is provided in the Supplementary material.
Estimation of absorbed doses
Groups of GPA33(+) SW1222 tumor-bearing mice (n=4 or 5) were given PRIT + 1.85 - Lu-DOTA-Bn during PRIT. In addition to the quantification of activity by gamma counting, the kidneys were collected from animals given PRIT + 11.1 -111.0 MBq and frozen at −80°C in OCT for autoradiography and histochemistry analysis. A detailed description of the autoradiography and histochemistry protocol is provided in the Supplementary material. injections on days 10 and 17 after tumor inoculation). For PRIT with nonspecific IgG-C825, an equivalent milligram dose of the GD2-targeted BsAb hu3F8-C825 [18] was used in place of huA33-C825, since it does not cross-react with SW1222 tumor. TVs were measured three times a week and the following definitions were used to describe treatment response: a complete response (CR) was defined as tumor shrinkage to 20 % of initial TV during treatment; a partial response (PR) was defined as a tumor showing no change in growth between successive measurements or any other tumor shrinkage not considered a CR; and an excessive tumor burden was defined as a final TV of >2,000 mm Lu-DOTA-Bn (details of the imaging method are provided in the Supplementary material) to verify tumorspecific versus nonspecific targeting as well as to assess whole-body clearance in mice receiving 177 Lu-DOTA-Bn alone [34] . Animals were observed until they were sacrificed due to excessive tumor burden (unless otherwise noted). Animals showing a weight loss greater than 15 % of their initial body weight in 1 or 2 days, or 20 % or more of their starting weight, were removed from the group at that time and sacrificed. To further evaluate toxicity, a total of eight randomly selected animals undergoing treatment were submitted for histopathologic assessment of the site of s.c. tumor, and assessment of the kidney, bone marrow (sternum, vertebrae, femur, and tibia), liver, and spleen by board-certified pathologists at the Memorial Sloan Kettering Cancer Center Laboratory of Comparative Pathology. Immunohistochemical (IHC) staining for the presence of GPA33 was also carried out in these mice using previously described protocols [8] . The maximum tolerated dose (MTD) was not determined in this study.
Results
In vitro characterization of huA33-C825
Biochemical purity analysis of huA33-C825 by sizeexclusion high-pressure liquid chromatography (SE-HPLC) is shown in Supplementary Fig. 2a . SE-HPLC showed a major peak (90 % by UV analysis) with an approximate molecular weight of 210 kDa, as well as some minor peaks assumed to be aggregates removable by gel filtration. The BsAb remained stable by SE-HPLC and Biacore after multiple freeze and thaw cycles (data not shown). The binding affinity was measured by Biacore T100. For GPA33, huA33-C825 had a k on of 9.
, and an overall K D of 63.5 nM-less than the parental huA33-IgG1 values (k on 6.
, and overall K D 1.71 nM; Supplementary Fig. 2b ). For antigen BSA-(Y)-DOTA-Bn, huA33-C825 had a k on of 1.
, a k off of 2.20× 10
, and an overall K D of 11.6 nM-comparable to the Supplementary Fig. 2c ). In summary, huA33-C825 retained high binding affinity to BSA-(Y)-DOTA-Bn, but lost considerable affinity to antigen GPA33.
Optimization of PRIT with huA33-C825, CA, and 177
Lu-DOTA-Bn
A combination of X-SPECT/CT imaging and ex vivo biodistribution studies of huA33-C825 PRIT + 177 Lu-DOTA-Bn were used to optimize huA33-C825 and CA doses during PRIT with the aims of achieving high uptake by the tumor while simultaneously minimizing exposure of radiosensitive normal organs such as the blood and kidney (see Supplementary Fig. 3) . A representative X-SPECT/CT image following PRIT + Lu-DOTA-Bn for blood, tumor, liver, spleen, and kidneys were 0.9, 65.8, 6.3, 6.6, and 5.3 cGy/MBq, respectively ( Table 1 ). The ratio of absorbed dose estimates for tumor to those for selected normal tissues (i.e., TI) ranged from about 10 (e.g., for liver, spleen, and kidney) to about 220 for muscle (Table 1) . Fig. 1d . The corresponding maximum intensity projection PET images are provided in Supplementary Fig. 4 . The CRC xenograft in the shoulder can be clearly delineated with minimal uptake in normal tissue and thus high overall contrast. The uptake in tumor was quantified by region-of-interest analysis of each of the calibrated PET images, and was determined to be 8. Lu activity decreased about four-fold for tumor with increasing administered activity (e.g., about 8.5 to 2 % ID/g for 2.0 MBq and 111.0 MBq, respectively), the relative 177 Lu activity in kidney remained <1 % ID/g and relatively constant (average range 0.46 -0.96 %ID/g), suggesting that saturation of available specific M-DOTA-Bn receptors by hapten was occurring in the tumor but not in the kidney compartments. The absolute 177 Lu activity uptake in tumor is shown in Fig. 2b , and was fitted to a one-phase association equation (GraphPad Prism version 6.00), with saturation apparent at a 177 Lu-DOTA-Bn activity of about 11 pmol/g of tumor (R 2 =0.89). Thus, during PRIT studies, 177 Lu-DOTA-Bn activities ≤55.0 MBq were considered subsaturating. Representative autoradiography and histochemistry data for kidney for three different 177 Lu-DOTA-Bn activity levels (11.1, 55.5, and 111.0 MBq) are shown in Fig. 2c . The 177 Lu activity appeared to be distributed predominantly in the renal cortex, with the cortex-to-medulla activity concentration ratios increasing with increases in administered 177 Lu-DOTA-Bn activity.
PRIT studies
A total of three separate therapy studies with 177 Lu-DOTA-Bn were conducted in SW1222 tumor-bearing mice to evaluate efficacy. A summary of all tumor response data as well as estimated absorbed doses for tumor, blood, and kidney for all PRIT groups is provided in Table 2 . No significant weight loss was observed in any of the control or treatment groups (data not shown). Lu-DOTA-Bn (antibody of interest, both n=8). Tumor response data from treatment groups are shown in Fig. 3 and Supplementary Fig. 6 . Representative scintigraphy images of selected treated mice are shown in Supplementary Fig. 7 and confirm specific tumor targeting during PRIT including huA33-C825 and 177 Lu-DOTA-Bn compared with controls and nonspecific PRIT. To summarize efficacy, no CRs were seen in any of the GPA33-targeted PRIT or control groups. Also, unremarkable PRs (slight tumor growth delays) were seen only in groups treated with huA33-C825 PRIT + In the second therapy study, a two-cycle regimen of huA33-C825 PRIT was investigated (n=4 or 5 per group; 10-day old tumors, TV 200 -700 mm 3 ). Similar to the first treatment study, the five untreated mice had to be sacrificed within 30 days due to excessive tumor burden, and the time to reach 500 mm 3 was 13±2 days (data not shown). Two of five animals treated with 2 × huA33-C825 PRIT + 11.1 MBq 177 Lu-DOTA-Bn (total 177 Lu-DOTA-Bn administered activity 22.2 MBq; estimated tumor absorbed dose 15 Gy) showed CR (Fig. 4a) . In the animals with recurrent tumors, the time to reach 500 mm Lu-DOTA-Bn administered activity 66.6 MBq; estimated tumor absorbed dose 44 Gy) showed CR (Fig. 4b) . In the animals with recurrent tumors, the time to reach 500 mm Lu-DOTA-Bn administered activity 111.0 MBq; estimated tumor absorbed dose 73 Gy) showed CR (Fig. 4c, left) . In the animals with recurrent tumors, the time to reach 500 mm 3 was 34, 42, and 45 days (average 40±6 days), and a single mouse had a tumor size of 44 mm 3 at 140 days. No major treatment-related toxicities were observed in eight of eight mice randomly selected for necropsy and pathologic assessment (pathologist summary provided in the Supplementary material). In addition, IHC staining of the tumor sections revealed that the residual tumor was GPA33-positive (Fig. 4d) .
Following these PRIT studies, we made some very approximate estimates of the number of clonogenic tumor cells remaining per mouse after dual-cycle treatment with huA33-C825 PRIT + 55.5 MBq 177 Lu-DOTA-Bn. We noted that the individual tumors that responded to treatment with a CR or greater dropped below the detection (palpation) threshold at about 12 days after the second treatment dose, or at about 30 days after inoculation of tumor cells (Fig. 4c) . This was used as time zero, from which regrowth of clonogenic cells would begin, to a volume of 500 mm 3 (i.e., recurrence). The estimated tumor-absorbed dose of 73 Gy resulted in CRs in four of four mice, including a single survivor without recurrence at 140 days. Based on an observed tumor doubling time of 5 days, the three tumors that recurred at approximately 35, 40, and 45 days (seven to nine doublings) after the nadir had an implied cell kill of 2 -3 logs. For the tumor without visible regrowth during the 140-day observation period, it was more difficult to estimate a cell kill because it may or may not have been cured. If the tumor had recurred at 140 days (28 doublings) after the nadir, the implied cell kill would have been approximately 8 logs. If we assume some numerical value for clonogenic cell density, it is possible to calculate how many logs of cell kill would be required to produce a significant probability of cure. For example, a clonogenic cell density of 10 9 cells per gram would imply that approximately 9 logs of kill are required to reduce a 500-mg tumor to a single surviving clonogenic cell. However, if the true number was 10 6 cells per gram, then only 6 logs of kill would be required. These values (and their associated uncertainties) translate into the amount of radiation dose that would be required to achieve a significant level of tumor cure. If an estimated tumor dose of 73 Gy gives approximately 3 logs of kill but 9 logs are needed (i.e., 10 9 cells/g), then the dose would have to be three times greater (i.e., 220 Gy). In contrast, if only 6 logs are needed (i.e., 10 6 cells/g) then the dose would need to be two times greater (i.e., 150 Gy). However, if the true number of clonogenic cells per gram was only 10 3 (e.g., a cancer stem cell-like scenario), doses similar to the current estimated value of 73 Gy would already be sufficiently high to produce a significant likelihood of tumor cure. Our experimental observation of a 25 % probability of cure seems to most closely resemble the last of these scenarios. Of course, in reality, we do not know what the clonogenic tumor cell density is, and tumor regression and regrowth are likely to be more complex than a simple monoexponential function, so these speculative calculations should be considered with caution.
Finally, a third PRIT study was performed at a ). All untreated mice showed similar tumor growth kinetics to those seen in previous studies (tumor doubling time about 5 days, data not shown). PRIT produced PR in three of the five mice as well as CR in two mice with delayed recurrence in one mouse (the time to reach 500 mm 3 was 65 days) and a single survivor without recurrence at 140 days (at 140 days after tumor inoculation, no measurable tumor at the site of s.c. injection; 10-day TV 121 mm 3 ; Fig. 4c, right) PR had to be sacrificed due to mobility concerns (unrelated to treatment) 18 days after treatment.
Discussion
We achieved our goal of demonstrating that a dosimetry-based TI could be used as a benchmark for successful therapeutic targeting by PRIT in CRC. We demonstrated mean TIs of about 73 for blood and 12 for kidney, and an estimated tumor dose of 43 -73 Gy with an estimated 2.1 -3.0 log kill at a 73-Gy tumor-absorbed dose, without detectable bone marrow and renal toxicity. We used 177 Lu-DOTA-Bn for theranostic RIT with administered activities up to 111.0 MBq delivered in a fractionated dose strategy (e.g., 2 × huA33-C825 PRIT + 55.5 MBq) to produce CR with 100 % frequency, including survival beyond 140 days in two of nine mice, with no major treatment-related toxicities observed. IHC analysis of the residual tumors revealed a GPA33(+) phenotype, suggesting that the reason for recurrence of some tumors was insufficient tumor-absorbed dose rather than escape by genetic mutation or some other mechanism. We also found that PRIT is a highly flexible approach that is readily adaptable to multiple dosing regimens, and in fact divided doses were more effective than equivalent single doses in inducing CR. Based on the absence of any treatment-related toxicities, all of our therapeutic regimens delivered normal-tissue absorbed doses well below the respective normal-tissue MTDs. Dose escalation could therefore safely proceed in this setting.
At the MTD, we anticipate that the normal tissues most sensitive to off-target radiotoxicity during anti-GPA33 PRIT would be bone marrow (using blood as a dosimetric surrogate for bone marrow), lung, liver, and kidneys (estimated absorbed doses 0.9, 1.8, 6.3, and 5.3 cGy/MBq, respectively; Table 1 ). Based on human normal-tissue radiation dose tolerance estimates derived from clinical observations [35] , the MTDs are 250 cGy for bone marrow, 1,500 cGy for lung, 3,000 cGy for liver, and 2,000 cGy for kidney. Therefore, we estimate that the maximum tolerated pretargeted 177 Lu-DOTA-Bn activity is 278 MBq, with the bone marrow as the dose-limiting organ. At this activity, the estimated absorbed dose delivered to tumor would be 18,292 cGy (183 Gy), with 250 cGy to blood (marrow) and 1,473 cGy to kidney.
We demonstrated that serial, noninvasive X-SPECT/CT imaging of s.c. GPA33(+) tumors was possible for PRIT with 177 Lu-DOTA-Bn, suggesting that quantitative imaging combined with therapy is possible (e.g., with QSPECT [36] Y has a complex spectrum, and radiation exposure is not insignificant. However, in a theranostic application, in which much larger treatment doses are anticipated, the gain from its use would outweigh the risk, because of the potential for improving patient selection and treatment planning. Also, corrections must be made for optimal reconstruction; notably, in addition to positrons, the large number of prompt gamma rays emitted by 86 Y can interfere with PET image quantitation, but accuracy can be significantly improved with correction algorithms [37, 38] .
During our investigation of anti-GPA33 PRIT, we made some notable observations regarding opportunities for improvement of current targeting reagents. First, the binding affinity of huA33 for its cognate antigen was reduced when the C825 was attached. Although we were able to achieve high TIs and apparently prolonged tumor retention during in vivo PRIT, the in vitro binding affinity data (Biacore) showed that huA33-C825 showed considerably lower affinity for antigen GPA33 as compared to parental huA33-IgG. This is consistent with modeling predictions of the affinity-dependence of tumor uptake, which indicate that large molecules (e.g., IgGs) are able to achieve similar uptake levels at much lower affinities in the 10 −8 to 10 −6 mol/L K d range, presumably due to the slow rate of intravasation allowing repeated binding withi n t h e t u m o r [ 3 9 , 4 0 ] . T h e C 8 2 5 a ff i n i t y f o r radiolanthanide Bn DOTA was unaffected. Nonetheless, we do not rule out the possibility that tumor targeting could be improved by affinity recovery, as well as by addressing other issues related to the pharmacokinetics and biodistribution of the BsAb [41] . These issues are currently under study. Second, uptake of the M-DOTABn by antibody prelocalized to tumor was only 10 % of that predicted on a picomolar basis. We speculate that the low maximum capacity is likely due to a combination of factors, including the metabolism of the dextran CA and subsequent leakage of small DOTA-dextran fragments into the circulation, and the in vivo stability (e.g., proteolytic) of the DOTA-binding scFv C825. Future studies will include alternative CA with improved serum stability, to reduce the likelihood of small DOTA hapten fragment leakage into the circulation following hepatic metabolism as well as using no-carrier-added formulations of 177 Lu-DOTA-Bn, which could offer an improvement of about three-fold in 177 Lu-specific activity (from about 1, 110 GBq/mg to a theoretical specific activity of 4, 033 GBq/mg Lu).
Successful development of a theranostic PRIT approach in CRC would meet an unmet need for cancer detection and management, and a platform-based PRIT paradigm may indeed be feasible using a variety of IgG-C825 antibodies targeting human cancers. Our previous investigations of PRIT, including PRIT of neuroblastoma based on hu3F8-C825 [18] , support the practicality of the platform concept. For one thing, once optimal clearing reagents and C825 haptens have been developed, these same reagents can be used as a component of theranostic approaches in combination with bifunctional antibody forms of antigen specificities for a broad spectrum of human tumors. In addition, direct applicability to most human tumors provides several possible advantages. First, radiation effects at high absorbed doses have wholly distinct patterns of resistance from that of current drugs and (nonradioactive) antibodies, and we therefore expect complementary effects to current drugs. Second, utilizing a theranostic approach, both diagnostic and therapeutic selection information can be obtained at Btracer doses.^This permits optimized patient dosing and the avoidance of treatment in patients whose tumors are not targeted by the antibody and who are therefore not likely to benefit from this treatment because of low tumor radiation dose or high dose to critical organs such as the kidney and gut. Furthermore, in this study we characterized the importance of the mass used in the three targeting steps and their effect on tumor localization and normal organ uptake. Similar data will need to be obtained in patients. To optimize these dose-seeking studies a modeling approach may be utilized [42] . Finally, a modular therapy in which the radioactivity is separated from the antibody infusion is appealing in a clinical setting, leading to an inherently multidisciplinary approach. For example, patient management and radiation safety measures are simplified.
Conclusion
Using a three-step PRIT protocol with the anti-GPA33/anti-DOTA(metal) BsAb huA33-C825, a dextran-based CA, and 
